Marsili Luca, Bologna Matteo, Chen Lily Y, Espay Alberto J
Department of Neurology, Gardner Family Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Cincinnati, OH, USA.
Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy; IRCCS Neuromed, Pozzilli, Isemia, Italy.
Neurol Clin. 2025 May;43(2):341-363. doi: 10.1016/j.ncl.2024.12.010. Epub 2025 Jan 22.
The most effective pharmacologic intervention used to treat motor symptoms in Parkinson's disease is levodopa, which is available in various formulations, including newer continuous subcutaneous infusions. Dopamine agonists, monoamine oxidase-B enzyme inhibitors, catechol-O-methyltransferase enzyme inhibitors, amantadine, istradefylline, and anticholinergics can be used as adjuncts to levodopa. With disease progression, pharmacologic interventions alone may not suffice to manage motor symptoms, making it necessary to consider device-aided therapies (eg, levodopa-carbidopa intestinal gel infusion, continuous subcutaneous infusions of apomorphine, levodopa, or foslevodopa) or invasive surgical techniques (eg, deep brain stimulation or MRI-guided high-frequency focused ultrasound).
用于治疗帕金森病运动症状的最有效药物干预是左旋多巴,它有多种剂型,包括新型的持续皮下输注剂型。多巴胺激动剂、单胺氧化酶-B酶抑制剂、儿茶酚-O-甲基转移酶酶抑制剂、金刚烷胺、异他司林和抗胆碱能药物可作为左旋多巴的辅助药物。随着疾病进展,仅靠药物干预可能不足以控制运动症状,因此有必要考虑器械辅助治疗(如左旋多巴-卡比多巴肠凝胶输注、阿扑吗啡、左旋多巴或福司左旋多巴的持续皮下输注)或侵入性手术技术(如深部脑刺激或MRI引导的高频聚焦超声)。